Last reviewed · How we verify
NCT04533542
Nicotine Vapor Specific Sensory Measurement
trial testing Measurement in Substance-Related Disorder in 42 participants. Completed in 7 March 2023.
7 March 2023
Quick facts
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 42 |
| Start date | 10 March 2021 |
| Primary completion | 7 March 2023 |
| Estimated completion | 7 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Measurement
- Questionnaire Administration
Conditions studied
- Substance-Related Disorder — all drugs for Substance-Related Disorder →
Sponsor
Roswell Park Cancer Institute
Who can join
Adults 21 to 55, any sex, with Substance-Related Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial aims to develop reliable and valid measures of sensory experiences unique to e-cigarette use. Regardless of whether flavorings show evidence of toxicity in a biological sense, they may nonetheless increase harm by other means, such as increasing appeal, decreasing risk perceptions, or masking harshness or irritation that might lead users to discontinue use.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04533542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Measurement
Trials testing the same drug.
- NCT06950879 — Validation Study Of A Digital Measuring Device For Central Hand Representation In Children With A Neonatal Brachial Plex · completed
- NCT06111040 — Nurturing Needs Study: Parenting Food Motivated Children · NA · recruiting
- NCT04155385 — Addiction Treatment Outcome Monitoring Study · NA · completed
- NCT03545737 — Compare a New Method and Formula as a Guide for the Intubation of a Left-sided Double-lumen Tube · completed
- NCT03199079 — Cervix Monitor for Elasticity and Length Measurements · completed
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
- NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
- NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
- NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
- NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04533542 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
- Last refreshed: 5 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04533542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing